Ginsenoside Rg3: Potential Molecular Targets and Therapeutic Indication in Metastatic Breast Cancer

Maryam Nakhjavani 1,2, Jennifer E Hardingham 1,2,*, Helen M Palethorpe 1,2, Yoko Tomita 1,2,3, Eric Smith 1,2,*, Tim J Price 2,3 and Amanda R Townsend 2,3

1 Molecular Oncology, Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia; maryam.nakhjavani@adelaide.edu.au (M.N.); helen.palethorpe@adelaide.edu.au (H.M.P); yoko.tomita@adelaide.edu.au (Y.T); eric.smith@adelaide.edu.au (E.S.)
2 Adelaide Medical School, University of Adelaide, Adelaide, SA 5005, Australia; timothy.price@sa.gov.au (T.J.P); amanda.townsend@sa.gov.au (A.R.T.)
3 Oncology Unit, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia
* Correspondence: jenny.hardingham@sa.gov.au; Tel.: +61-8-8222-6142

Received: 20 December 2018; Accepted: 23 January 2019; Published: 23 January 2019

Abstract: Breast cancer is still one of the most prevalent cancers and a leading cause of cancer death worldwide. The key challenge with cancer treatment is the choice of the best therapeutic agents with the least possible toxicities on the patient. Recently, attention has been drawn to herbal compounds, in particular ginsenosides, extracted from the root of the Ginseng plant. In various studies, significant anti-cancer properties of ginsenosides have been reported in different cancers. The mode of action of ginsenoside Rg3 (Rg3) in in vitro and in vivo breast cancer models and its value as an anti-cancer treatment for breast cancer will be reviewed.

Keywords: Ginsenoside Rg3; breast cancer; AQP-1; epimer; angiogenesis

1. Metastatic Breast Cancer

Metastatic breast cancer (MBC) is classified as stage IV where the tumor has metastasized to distant organs such as bones, lungs, liver, or brain [1]. Breast tumors are subdivided into different categories based on the receptors expressed in the cells: estrogen receptor (ER)- or progesterone receptor (PR)-positive, human epidermal growth factor receptor 2 (HER2) positive, and triple negative breast tumors (ER/PR/HER2) (Figure 1). Hormone receptor expressing tumors including luminal A or luminal B subtypes constitute the largest portion of patients and have the best prognosis, as these tumors are inherently less aggressive compared to other subtypes of breast cancer and that the majority of these tumors are responsive to hormone therapy options such as tamoxifen or letrozole [2]. HER2-expressing tumors constitute 15–20% of the patients [3]. The prognosis of this group of patients has improved following the introduction of targeted anti-HER2 medications, such as trastuzumab [4]. Some 15% of patients have triple negative (basal-like) breast cancer (TNBC) [5] and for these patients, chemotherapy remains the main treatment option [6]. TNBC is associated with younger age (<50 years) at diagnosis and BRCA1 mutation, and by the time of diagnosis have larger tumor size, higher grade tumor and the worst prognosis [7]. Recently, inhibitors of poly ADP ribose polymerase (PARP) have been found to be effective in the treatment of TNBC patients with BRCA-1 or -2 mutations. Likewise, platinum-based cytotoxic drugs are being tested in such patients [2]. However, still there is no ultimate cure for MBC and these patients suffer from the side effects of chemotherapy, until the tumor develops acquired resistance [8] and the patients succumb to the disease. Hence, many cancer researchers are actively looking for better treatment options to improve the quality of life of the MBC patients, reduce the toxicities of the chemotherapy regimens, restrict tumor metastasis, and improve survival. In this
review, the medicinal herb ginseng and the important group of chemicals in its extract are suggested as one such therapy with the potential for reduced toxicity.

Figure 1. Subtypes of metastatic breast cancer, based on receptor expression. Hormone-receptor expressing tumors are treated with anti-hormone therapy (such as tamoxifen), HER2-expressing tumors are given targeted anti-HER2 monoclonal antibody therapy such as trastuzumab. The main treatment option for triple negative breast tumors is chemotherapy.

2. Ginseng—History and Medicinal Use

Ginseng, with a long history of human use as a traditional medicine, has various pharmacological effects [9–11], and is widely used for its nutritional value as a food, energizing the body [10], improving body performance in sports, relieving menopausal symptoms, and alleviating sexual dysfunction [12]. Panax ginseng, also known as Chinese or Korean ginseng is a species of ginseng, the extract of which has the highest medicinal value among other species. Ginsenosides are the group of chemicals in this extract having the highest medicinal value [13]. So far, 38 ginsenosides have been identified [14]. Ginsenosides are saponins having a steroid-like hydrophobic backbone connected to sugar moieties. Based on their chemical structure, they are categorized into panaxadiol, panaxatriol, and oleanolic groups [13], with propanaxadiols being the most abundant group. Protopanaxadiols include Rb1, Rb2, Rg3, Rh2, Rc, Rd, Ra, and F2 [12] and have various medicinal properties, including anti-diabetic effects, protection against cardiovascular diseases and anticancer properties [10,12].

Not all of these protopanaxadiols are available in ginseng extract. Commercial ginseng is produced either by air-drying or steaming (120°C, 4 h) the plant. These processes produce white or red ginseng, respectively [15–17]. Due to the conversions and chemical changes following heating, the heat processed or red ginseng has higher medicinal properties than white ginseng. Within this heating process, polar ginsenosides such as Rb1 or Rb3 convert to less polar ginsenosides such as Rg2 and Rg3 [15,18].

Ginsenoside Rg3 is one of the well-studied members of protopanaxadiols, and arises following loss of the sugar moiety on C20 in the heating process. Like other ginsenosides, Rg3 has a stereocenter on C20, giving it two epimers; 20(R)- and 20(S)-ginsenoside Rg3 (Figure 2). This is due to the selective attachment of the hydroxy group to the C20 after losing the sugar structure. In the 20(R)-Rg3 epimer, the hydroxyl on C20 is far from the hydroxyl on C12, whilst in 20(S)-Rg3, these two hydroxyls are close to each other. Also, the alkene chain connected to C20 in 20(R)-Rg3 is more flexible compared to its fixed orientation in 20(S)-Rg3. This makes the alkene in 20(S)-Rg3 less accessible to water and more prone to hydrophobic interactions while leaving the hydroxyl groups to interact with the receptors. This may play a part in the increased water solubility of 20(S)-Rg3 compared with 20(R)-Rg3 [19,20].
3. Epimers of Ginsenoside Rg3 in the Treatment of Cancer

Depending on the biological system being tested, the two epimers of ginsenoside Rg3, 20(S)- and 20(R)-Rg3, have distinct effects. For example, while both epimers inhibited the 5-HT₃A and αβ4 nACh receptors, only 20(S)-Rg3 inhibited the voltage-dependent Ca²⁺, K⁺, and Na⁺ channel currents [21,22]. The 20(S)-Rg3 was also a better scavenger of hydroxyl radicals [23] and in the human gastric cancer cell line AGS, was responsible for inducing apoptosis (through activation of caspase-3, -8, and -9) [24]. In human hepatocellular carcinoma cell line HepG2, 20(S)-Rg3 was the more effective epimer in inhibiting cell growth, downregulating the expression of DNA methyltransferases, reducing global DNA methylation, and in particular, modifying the methylation of the promoter region of some relevant genes in cancer such as VEGF, TP53, and BCL-2 [25].

In contrast, 20(R)-Rg3 was a better antioxidant against the oxidative stress induced by cyclophosphamide in mice [26] and can promote the immune response in mice better than 20(S)-Rg3 [27,28]. It was also a better inhibitor of tumor growth in mice bearing H22-transplanted hepatocellular tumors [28]. Epimers of Rg3 have also been tested in epithelial–mesenchymal transition (EMT) in lung adenocarcinoma in vitro models. For instance, 20(R)-Rg3 epimer inhibited EMT via increasing the expression of E-cadherin and inhibiting the expression of vimentin and upregulation of Snail [29].

4. Mechanisms of Action of Ginsenoside Rg3 in Breast Cancer

Regardless of the stereotype, Rg3 has been studied in several cancer models and various mechanisms are suggested for its actions. These mechanisms include induction of apoptosis [24,30–52], induction of autophagy through upregulation of autophagy-associated molecules [53], inhibition of proliferation [24,25,38,41,42,44–46,50,51,54–63], inhibition of metastasis [29,50,62,64–71] and angiogenesis [55,56,66], cell cycle arrest [47], immunomodulatory effects [72], sensitization to radiation [73], reducing multidrug resistance [74], and inducing genotoxicity to the cancer cells [75]. A few studies have focused on the effects of Rg3 in breast cancer models; these mechanisms are discussed as follows.
4.1. Induction of Apoptosis and Inhibition of Proliferation

Induction of apoptosis is one of the most studied mechanisms of action of Rg3 in different cancers. Apoptosis is a complex process, regulated by extrinsic (via the death receptor) and intrinsic (via mitochondrial) pathways. The intrinsic pathway is activated by DNA damage and oxidative stress whilst the extrinsic pathway can be triggered by the activation of the members of the TNF receptor superfamily. Both pathways ultimately activate caspase enzymes.

Caspases can interact with an apoptosis inhibitor such as inhibitors of apoptosis proteins (IAP) and the Bcl-2 family. Caspases can also go through auto-activation and cleave other substrates, one of which is PARP, an important DNA repair enzyme. In a TNBC cell line, MDA-MB-231, Rg3 activated caspase-3, and degraded PARP through the generation of reactive oxygen species (ROS) [30]. In addition, Rg3 caused an increased ratio of pro-apoptotic Bax and the anti-apoptotic Bcl-2 [30]. Also, it inhibited the binding of NF-κB to DNA. NF-κB is a transcription factor that is constitutively active in breast cancer cells and drives further cell cycle progression, proliferation and inhibition of apoptosis. Proteins Akt and ERK are two kinases involved in the activation of NF-κB and it is observed that in MDA-MB-231 cell line, Rg3 inhibited the phosphorylation of Akt and ERK and hence prevented the activation of NF-Kb [31]. P53, a tumor suppressor protein, has a negative regulatory effect on Bcl-2 while mutant P53 can prolong the activation of NF-κB and affect the apoptosis of cancer cells. In MDA-MB-231 cells, Rg3 destabilized mutant P53, suppressed the expression of Bcl-2, and induced apoptosis [31]. Figure 3 summarizes these mechanisms.

Inhibition of proliferation is another important function proposed for Rg3. For example, in in vivo settings, Rg3 has shown inhibition of tumor growth in the cancer models of colon [54], lung [38,72], liver [39], pancreas [76], and gallbladder [32]. As a specific epimer, 20(S)-Rg3 has caused similar responses in tumors of the gallbladder [47] and ovary [51,68] and 20(R)-Rg3 in melanoma [61,63], lung [62], and liver [28] cancer models. In vitro, in MCF-7 breast cancer cell lines, 20(S)-Rg3 (100–300 µM) caused a cell cycle arrest in G1-phase and hence inhibited cell proliferation [57]. Table 1 shows other suggested mechanisms of Rg3 in induction of apoptosis and inhibition of proliferation in other cancer models.

4.2. Inhibition of Migration, Invasion, Angiogenesis, and Metastasis

Ginsenoside Rg3 has been shown to reduce the migration, invasion, and angiogenesis of human umbilical vein endothelial cells (HUVECs) both in vitro and in vivo. Treatment of HUVECs with 20(R)-Rg3 reduced cell viability with an IC50 of 10 nM. There was a dose-dependent reduction in the tube forming capacity of these cells (1-1000 nM) and inhibition of VEGF-induced chemo-invasion in vitro. In vivo Rg3 inhibited angiogenesis (150 and 600 nM) in a matrigel plug assay. The mechanisms suggested were inhibition of matrix metalloproteinase (MMP)-2 and -9 [77].

Rg3 has been shown to degrade serum levels of IGF-1 and hence inhibits angiogenesis and tumor growth in breast cancer [78]. In a study by Chen et al. [69], in the MDA-MB-231 cell line, 20(S)-Rg3 decreased the expression of CXCR4, an important chemokine receptor expressed by breast cancer cells which is involved in migration and invasion (Figure 3) [69]. Other suggested mechanisms for this action in other cancer models include decreased expression of MMP-2 [29,77], -9 [66], and -13 [67], reducing the expression of HIF-1α [55,68], AQP1 [71], and HDAC3 [63], suppressing NF-κB and its products (c-Myc, COX-2, MMP-9) [55,64], inhibiting TGF-β1, inactivating proteins involved in EMT (p38 MAPK and Smad2) [29,55], downregulating FUT4 and EGFR mediated migration through MAPK and NF-κB [55,62], and decreasing the expression of VEGF [55] and VEGF dependent p38/ERK signaling [56] (Table 2). Rg3 has also resulted in an increased survival in mice bearing melanoma [50] and liver tumors [39].
4.3. Multidrug Resistance (MDR) and Combination Therapy

Rg3 can decrease MDR via inducing membrane fluidity and blocking drug efflux in leukemia cell lines [74]. In the Caco-2 cell line, 20(S)-Rg3 (80 µM) was shown to inhibit P-glycoprotein (Pgp) [79]. It has also been shown to increase the accumulation of drugs such as vincristine in MDR cells, but not in sensitive cells [80]. Likewise, mice bearing MDR tumors showed an increased survival time and less tumor weight when treated with a combination of doxorubicin and Rg3, rather than doxorubicin alone [80].

Few studies have shown the effects of co-administration of Rg3 and a chemotherapy agent in breast tumor models. What is known so far is that mice bearing breast tumors that received a combination of continuous low-dose capecitabine, a prodrug of fluorouracil (5-FU), and Rg3 showed less toxicity induced by capecitabine, longer survival, and reduced susceptibility to drug resistance [81]. This is in part due to the antiangiogenic effect of Rg3 as evidenced by the decreased VEGF expression and reduced microvasculature density. The outcomes of this study are promising for the oral administration of capecitabine and improvement in tolerance of the patients.

In addition, Rg3 when co-administered orally with paclitaxel, significantly increased the relative bioavailability of paclitaxel and decreased the relative breast tumor growth rate in mice bearing MCF-7 xenograft [79]. Rg3 has been tested in other cancer models in combination with cyclophosphamide [82,83], gemcitabine [84], temozolomide [85], cisplatin [86–88], docetaxel [89,90], doxorubicin [91,92], and As$_2$O$_3$ [93] (Table 3).

![Figure 3. Rg3 inhibits cell proliferation and induces apoptosis via different effector molecules and pathways, in MDA-MB-231 cell line [30,31]. Changes in specific molecules involved in signalling pathways upon exposure of the cells to Rg3 is shown in this figure. The ↑ and ↓ arrows are indicating increased and decreased levels of certain molecules, respectively, and the × signs show the inhibition of a signalling pathway or function of a certain protein in the MDA-MB-231 cell line.](image-url)
Table 1. Suggested mechanisms for induction of apoptosis (IA) and inhibition of proliferation (IP) by Rg3 in various cancers are summarized in Table 1. The function of different epimers are indicated by symbols; * and ♦ represent 20(S)- and 20(R)-Rg3, respectively.

| Cancer        | Mechanism of Action                                                                 | Reference   |
|---------------|-------------------------------------------------------------------------------------|-------------|
| Ovary         | Downregulation of PI3K/Akt and the proteins of the IAP family *                     | [52]        |
|               | Activation of caspases -3 and -9 *                                                   |             |
|               | Inhibition of Warburg effect by inactivation of Stat3 *                              | [51]        |
|               | Suppression of the Warburg effect and modulating the Stat3/HK2 pathway               |             |
| IP            | Activation of AMPK *                                                                | [45,46]     |
|               | Increased DNA fragmentation, cleavage of PARP *                                     |             |
| Colon         | Activation of AMPK *                                                                | [45,46]     |
|               | Increased DNA fragmentation, cleavage of PARP *                                     |             |
|               | Inhibition of β-catenin and the β-catenin/Tcf signalling *                          | [54]        |
| IP            | Inhibits cell proliferation                                                         |             |
|               | Reduced mitosis-related proteins *                                                  | [46]        |
|               | Reduced DNA-repair proteins *                                                       |             |
| Lung          | Regulation of apoptosis-associated proteins such as BCL2, BAX, PARP-1              | [38,40,41]  |
|               | Cleaving caspase-3                                                                  |             |
|               | Inhibition of EGFR, Stat3, Akt and PI3/Akt signalling                               | [38,62]     |
| Liver         | Increasing the activity of caspase-3 and expression of Bax                          | [35]        |
|               | Inhibiting the secretion of IGF-1                                                  | [42]        |
|               | Activating caspases -3 and -9                                                       | [48]        |
| Multiple       | Suppression of some of the cell cycle proteins such as cyclin D1 and E, CDK-2 and  | [41]        |
| myeloma       | Suppression of some of the MAPK-associated growth proteins such as JNK, ERK and P38 |             |
| Leukaemia     | Activation of intrinsic and extrinsic pathways                                      | [39,44,49]  |
|               | Sensitizing liver cancer cells to TRAIL-induced cell death                          | [43]        |
|               | Promoting TRAIL-induced caspase-dependent apoptosis                                 |             |
| Gallbladder   | Increasing caspase-12 (an endoplasmic reticulum stress-mediated apoptosis)           | [32]        |
|               | Activating intrinsic and extrinsic apoptosis pathway *                              | [47]        |
|               | Inducing cell senescence *                                                         |             |
| Gastric       | Activation of the intrinsic and extrinsic pathways through increasing                | [24,34]     |
|               | Bax, caspase-3, release of cytochrome c, decreasing Bcl-2, Bcl-xL                   |             |
|               | Blocking TRMP7                                                                      |             |
|               | Inhibiting the expression of caspase and Bcl-2 *                                    | [24,33]     |
| Melanoma      | Preparing the binding of NF-xB to the FUT4 promoter                                  | [36]        |
|               | Activating intrinsic and extrinsic apoptosis pathways                               |             |
|               | Inhibiting the expression of caspase and Bcl-2 *                                    | [50]        |
|               | Decreasing the levels of active Akt *                                              | [50]        |
|               | Dysregulating the PI3K/Akt pathway, hence affecting the cell cycle *                |             |
|               | Inducing a G0/G1 cell cycle arrest                                                   | [63]        |
|               | Increasing the acetylation and stability of p53                                      | [61]        |
|               | Reducing FUT4 and LeY                                                               |             |
|               | Inhibiting the EGFR/MAPK signalling pathway                                         |             |
| Glioblastoma  | Suppressing the MEK/MAPK signalling pathway and activating ROS by the antioxidant   | [37]        |
| multiforme    | enzyme system, leading to apoptosis                                                 |             |
| Prostate      | Affecting the MAPK activity through ERKs, p38 and JNK *                             | [59]        |
| Glioma        | Activating Akt and p53/p21 dependent signalling pathways causing                     | [60]        |
|               | cell senescence *                                                                  |             |
Table 2. Suggested mechanisms of inhibition of migration and invasion in different cancer models. The function of different epimers are indicated by symbols; * and ♦ represent 20(S)- and 20(R)-Rg3, respectively.

| Cancer               | Mechanism                                                                 | Reference |
|----------------------|---------------------------------------------------------------------------|-----------|
| Ovary                | Inhibition of angiogenesis and cell invasion                               | [66]      |
|                      | Decreased expression of MMP-9                                              |           |
|                      | Blocking the EMT *                                                         | [68]      |
|                      | Reducing HIF-1α expression *                                               |           |
| Colon                | Suppressing NF-κB and its products (c-Myc, COX-2, MMP-9)                  | [64]      |
| Prostate             | Decreasing the expression of AQP1 *                                       | [71]      |
| Melanoma             | Inhibiting the expression of MMP-13                                        | [50,67,70]|
|                      | Reducing cell adhesion, invasion and angiogenesis *                        |           |
|                      | Decreasing the expression of HDAC3 ♦                                      | [63]      |
| Lung                 | Inhibiting TGF-β1                                                          | [29]      |
|                      | Inactivating proteins involved in EMT (MMP-2, p38 MAPK and Smad2) ♦       |           |
|                      | Downregulating FUT4 and EGFR mediated migration (through MAPK and NF-κB) ♦|           |
| Endothelial progenitor cells | Decreasing the activation of the VEGF dependent p38/ERK signalling | [56]      |
| Esophageal and renal | Decreasing the expression of VEGF                                          | [55]      |
|                      |                              |           |

4.4. Aquaporin (AQP) 1—a Putative Target of Rg3

One suggested mechanism of action of Rg3 is by targeting AQP1 [71]. This molecule has roles in tumor growth, angiogenesis [94–96], metastasis [97,98], acquired resistance in tumors [99], and is highly expressed in aggressive tumors [100]. AQP1 is a member of the family of AQP membrane channels which are primarily known for their role in water transport across the lipophilic cell membrane. AQP1 was the first of the 13 members of the AQP proteins to be discovered [95,101,102]. It is a unique AQP in that, as well as acting as a water channel, it has a second function of transporting single charged cations, regulated by cGMP gating. AQP1 also transports gases such as nitric oxide, carbon dioxide, and ammonia (Figure 4) [102–105]. Rg3 was found to inhibit expression of AQP1 at both the mRNA and protein levels. Further, in a prostate cancer cell line (PC-3M), Rg3 (up to 10 µM) did not affect cell proliferation but inhibited cell migration in a transwell assay. Overexpression of AQP1 in this cell line attenuated the effect of Rg3 in inhibiting migration while silencing AQP1 gene via shRNA resulted in reduced PC-3M cell migration, and a diminished response to Rg3. These results indicated a critical role for AQP1 mediating the anti-migratory role of Rg3 [71]. This suggests that Rg3 targeting AQP1 could also be relevant in breast tumors.

Figure 4. The structure of AQP1 channel, as a homotetramer, with the dashed arrow showing the water passage through the water channel of each monomer. The solid violet arrow represents the passage of ions and gases. The 3D structures were prepared in PyMol, version 1.7.4.5 (Schrödinger, Inc, Tokyo, Japan).
AQP1 and Breast Cancer

In vitro data suggest that stable overexpression of AQP1 in MCF-7 (ER+ and PR+) and MDA-MB-231 (TNBC) breast cancer cell lines significantly increases cell invasion and proliferation [106]. In HUVECs, expression of AQP1 is known to be upregulated by estrogen, because the promoter of the AQP1 gene has a functional estrogen response element (ERE) and the homodimerized complex of estrogen-ER can activate this ERE [107]. AQP1 is expressed in all microvasculature endothelial cells including HUVECs. In HUVECs, estrogen increased the proliferation, migration, invasion, and tube forming capacity, and these effects were inhibited by knockdown of AQP1 expression using siRNA [107]. Epidermal growth factor stimulation induced translocation of AQP1 from the cytoplasm to the cell membrane to enhance cell invasion [106]. AQP1 was also found to colocalize with ezrin, a cytoskeletal protein involved in the proliferation, cell adhesion, and NO production in the endothelial cells [107].

Animal studies show that AQP1 is highly expressed in mouse breast tumor [108], and AQP1-null mice show impaired angiogenesis [109]. In mouse models of breast carcinoma with lung metastasis, AQP1 deficiency decreased the expression of VEGFR2 leading to significantly reduced tumor mass and volume, microvasculature density, and the number of lung metastases [110].

In humans, AQP1 is abundantly expressed in the endothelium of many tissues [111] including the endothelium of tumor micro-vasculature, positive for CD31 [100,107]. In normal breast tissues, the expression of AQP1 is low and limited to the ducts, lymphatics and connective tissue microvessels [112]. Breast cancer is one of the tumors with increased microvessels and angiogenesis compared to its matched normal tissue and there is an increased AQP1 expression in the microvasculature of breast tumor [112,113]. Breast tumors of basal-like TNBC subtype and advanced breast tumors have higher levels of AQP1 expression compared to normal tissues [112–114]. Benign breast lesions and ductal carcinoma in situ samples express AQP1 on the membrane of myoepithelial cells of the ducts, but the majority of invasive ductal carcinoma samples predominantly express AQP1 in the cytoplasm [106,115]. So far, studies have shown that membrane AQP1 expression is associated with triple-negativity, expression of cytokeratin 14 and smooth muscle actin, higher tumor grade, medullary-like histology and poor clinical prognosis [113,114]. High AQP1 expression was found to be an independent prognostic factor in the high-grade subgroup, in the ER-negative subgroup and in the node-negative subgroup [114]. Cytoplasmic expression of APQ1 is correlated with lymph node metastasis and advanced features of invasive ductal carcinoma [106].

4.5. Other Suggested Mechanisms of Action

Rg3, when orally administered to mice bearing lung tumors, had immunomodulatory effects, causing increased splenocyte proliferation [72]. It also increased genotoxicity in osteosarcoma cell lines, through increased DNA damage and double-strand breaks [75]. This compound sensitized lung cancer tumors to radiation via suppressing the activation of NF-κB and the proteins regulated by this transcription factor (such as COX2, MMP-9, VEGF, c-Myc, and cyclin D1), which are either induced by radiation or are involved in radio-resistance [73].
### Table 3. Suggested effects of Rg3 in combination with chemotherapy agents in in vitro and in vivo models.

| Studied Model                          | Drug Combination              | Effects                                                                 | Reference |
|----------------------------------------|-------------------------------|------------------------------------------------------------------------|-----------|
| Lewis lung cancer mouse model          | Rg3 + cyclophosphamide (continuous low-dose) | Less toxicity induced by capecitabine                                  | [82]      |
|                                        |                               | Long animal survival                                                   |           |
|                                        |                               | Reduced susceptibility to drug resistance                              |           |
|                                        |                               | Increased anti-angiogenic activity                                     |           |
|                                        |                               | Inhibiting cyclophosphamide-induced DNA damages in the peripheral lymphocyte cells and bone marrow cells | [83]      |
|                                        |                               | Reducing number of apoptotic cells of mice and improving the anti-oxidative markers in mice (such as SOD, MDA and GPX) |           |
| Mouse model                            | 20(S)-Rg3 + cyclophosphamide | Alteration of the expression of Bcl-2 family and induction of intrinsic pathway of apoptosis | [39]      |
| Mouse bearing hepatocellular carcinoma model | Rg3 + cyclophosphamide    | Enhancing the efficacy of gemcitabine on suppressing tumor growth      | [84]      |
|                                        |                               | Increasing the quality of life                                         |           |
|                                        |                               | Prolonging mice survival                                               |           |
|                                        |                               | Decreasing VEGF expression, microvessel density (assessed by the expression of CD31) and arterial blood flow in tumors such as peak systolic velocity |           |
| Mouse bearing lung tumor model         | Rg3 + gemcitabin              | Improving the antiangiogenic effects of temozolomide                   | [85]      |
|                                        |                               | No additive effect on tumor growth                                     |           |
| Glioma cell line                       | Rg3 + temozolomide            | Inducing cell cycle arrest and apoptosis                              | [85]      |
| Glioma allograft model of mouse        | Rg3 + temozolomide            | Attenuating the expression of VEGF-a and Bcl-2                        | [85]      |
|                                        |                               | Antiangiogenic effect (reduced relative cerebral blood volume, VEGF levels and microvessel density) |           |
| Mouse bearing colon tumor              | Rg3 + cisplatin               | Improving anti-cancer effects of cisplatin                             | [86]      |
|                                        |                               | Inhibiting tumor growth                                                |           |
|                                        |                               | Reducing the toxicities of cisplatin (decreasing the intracellular levels of ROS) | [86]      |
|                                        |                               | Decreasing the high levels of detoxifying enzymes such as heme-oxygenase (HO-1) and NAD(P)H quinone oxidoreductase (NQO-1) |           |
| Kidney, liver and colon resistant cancer cells | Rg3 + cisplatin     | Synergistic effect in inhibiting the proliferation (possibly through activating the intrinsic apoptosis pathway (decreased Bcl-2 and increased cytochrome c and caspase-3) and cell cycle alterations in G2/M phase) | [87]      |
| Cisplatin-resistant bladder tumor cell lines | Rg3 + cisplatin | Enhancing the inhibitory effects of cisplatin                          | [88]      |
|                                        |                               | Reducing the proliferation of cancer cells                             |           |
|                                        |                               | Decreasing the microvascular density of the tumors                     |           |
| Mouse bearing oesophageal squamous cell carcinoma | Rg3 + cisplatin | Sensitizing the cells to the docetaxel                                 | [89]      |
|                                        |                               | Improving its apoptotic effect (via inhibiting NF-κB and the expression of anti-apoptotic proteins such as Bcl-2, XIAP, and cyap-1) |           |
|                                        |                               | Increasing the expression of pro-apoptotic proteins (such as Bax, caspase-3 and -9) |           |
| Colon cancer cell lines                | Rg3 + docetaxel                | Inhibiting cell growth                                                 | [90]      |
|                                        |                               | Inducing apoptosis and its associated protein                          |           |
|                                        |                               | Arresting the cells at G0/G1                                           |           |
|                                        |                               | Modulating cell cycle-associated proteins                              |           |
|                                        |                               | Inhibiting the activity of NF-κB                                       |           |
Table 3. Cont.

| Studied Model | Drug Combination | Effects | Reference |
|---------------|------------------|---------|-----------|
| Prostate cancer cell lines | Rg3 + docetaxel + cisplatin | More effective inhibition of the activity of NF-κB and cell growth | [90] |
| Mouse bearing hepatocellular tumor | 20(S)-Rg3 + doxorubicin | Suppressing the autophagy via regulating autophagy-associated proteins Inhibiting autophagic flux Synergistic effects in inhibiting tumor growth Reducing doxorubicin-induced cardiotoxicity (by improving the ejection fraction, fractional shortening and left ventricular outflow) Improving the oxidative damage and apoptosis induced by doxorubicin (via the activation of Akt and the Nrf2-ARE pathway) | [91] [92] |
| Rat model | Rg3 + doxorubicin | | |
| NCI-H1299 lung cancer cells | Rg3 + As2O3 | Inhibiting the proliferation of NCI-H1299 lung cancer cells | [93] |
| Mouse bearing lung tumors | Rg3 + As2O3 | Promoting apoptosis in tumor cells Prolonging the survival of the mice | [93] |

5. Metabolism and Pharmacokinetics of Rg3

Together with the clinical trials, it is pertinent to consider the pharmacokinetics of Rg3 following oral administration. So far, various studies have focused on the metabolism and pharmacokinetics of Rg3, as a general compound, and 20(R)-Rg3 in in vitro, animal models and healthy human volunteers. It is not yet clarified whether the metabolism of 20(S)- and 20(R)-Rg3 differ in any aspects. The general understanding is that following oral administration, ginsenosides undergo a partial or complete hydrolysis in the acidic conditions of the stomach and the intestinal microbial flora [116,117]. Rg3, like other protopanaxadiol ginsenosides, can lose a sugar moiety following metabolism by the anaerobic intestinal bacteria [118]. Compound K, the final metabolite of the metabolism of ginsenosides can be detected in human plasma after seven hours post-ingestion [118].

In vitro studies have shown that Rg3 has interactions with isoenzymes of cytochrome P450. Rg3 can weakly inhibit CYP3A4, moderately inhibit CYP2C19 and CYP1A2, and potently inhibit CYP2D4 [119] and so interactions between Rg3 and the drugs that are mainly metabolized with these isoenzymes should be considered. Also, incubation of Rg3 with human fecal microflora resulted in the formation of ginsenoside Rh2 [120], another member of the ginsenoside family with anticancer properties [121]. Studies in dogs however failed to detect any Rh2 in the plasma samples following oral or intravenous (IV) administration of 20(R)-Rg3 [122]. Although in vitro studies suggest that deglycosylation is one of the main pathways of the metabolism of Rg3, this study failed to show existence of such molecules in dog plasma samples [122]. This study also suggested a low degree of metabolism of 20(R)-Rg3, as evidenced by the maximum of 70% of 20(R)-Rg3 recovered from bile [122].

In rats, deglycosylation and oxygenation are reported as two major routes of metabolism for 20(R)-Rg3 [123]. The half-life of Rg3 in rats after an intravenous administration is reported to be 14 min [124] and 18.5 min [123]. The difference between these two reports might be due to the difference in the solubilisation of Rg3, however, both suggest a rapid rate of metabolic clearance for this molecule. Absolute bioavailability of Rg3 in rats was about 2.63% [125].

Intra-species differences seem to play an important role in the metabolism and pharmacokinetics of Rg3, since in healthy human volunteers, Rg3 can be detected in the plasma for 8 [126,127] and up to 216 hours [126], following oral and intramuscular (IM) administration, respectively.

The epimers of Rg3 also differ in terms of tissue distribution. 20(S)-Rg3, following oral administration of 68 mg/kg to Sprague–Dawley rats was more concentrated in the gastrointestinal tissues compared to the plasma. It was also highly distributed in the liver, with the concentration being four and three times the plasma concentration at two and four hours, respectively. The concentration of Rg3 in other tissues such as muscle, spleen, lung, and fat was similar or lower than plasma concentration and trace amounts were detected in the brain, heart, and kidney. However, 20(R)-Rg3
was only localized in liver and the gastrointestinal tract, and not detected in the plasma [128]. Table 4 summarizes the results of the studies on the pharmacokinetics of Rg3 in animal models and human trials.

| Ginsenoside | Model | Route | Dose | Sample | Detected Rg3 | Outcomes | Reference |
|-------------|-------|-------|------|--------|--------------|----------|-----------|
| Rg3         | Sprague-Dawley rats | IV    | 1 mg/kg | Plasma | Detected for 12 h | $t_{1/2a}: 0.12 \pm 0.03 h$ | [125] |
|             | Oral  | 10 mg/kg | Plasma | Detected for 12 h | | $t_{1/2a}: 2.09 \pm 0.50 h$ | |
| Healthy humans | Oral  | 3.2 mg/kg | Plasma | Detected for 8 h | | $C_{max}: 15.62 \pm 6.14$ ng/mL | [129] |
| Healthy humans | IM    | 10, 30 and 60 mg | Plasma | Detected for 216 h | | $t_{1/2}: 14$ min | [126] |
| Rg3         | Sprague-Dawley rats | IV    | 5 mg/kg | Plasma | Detected for 1.5 h | $t_{1/2}: 14$ min | [124] |
|             | Oral  | 50 mg/kg | Urine | Not detected in 1 h | | rapid GI metabolism | |
| 20(R)-Rg3   | Dogs  | IV    | 0.3 mg/kg | Plasma | Detected for 12 h | $t_{1/2}: 1.71 (\pm 0.11) h$ | [122] |
|             | Oral  | 2 mg/kg | Plasma | Detected for 24 h | | $t_{1/2}: 5.99 (\pm 1.16) h$ | |
|             | IV    | 5 mg/kg, within 1 min | Plasma | Detected for 1.5 h | | $t_{1/2}: 18.5$ min | N/A |
|             | Oral  | 100 mg/kg | Urine | Not detectable | | N/A | [123] |
|             |       |       | Feces | 6 different deglycosylated and oxygenated metabolites | | | |
| Healthy humans | Oral  | 3.2 mg/kg | Plasma | Detected for 8 h | | $C_{max}: 0.66 \pm 0.10$ h | [127] |

6. Clinical Trials

6.1. Application and Safety of Ginseng Extract on Healthy Human Volunteers

Studies on healthy human volunteers suggest that administration of the total extract of Panax ginseng C.A. Meyer is well tolerated and does not cause serious adverse reactions [130,131]. In a randomized, double-blind, placebo-controlled trial investigating the anti-oxidant properties of the total extract, 82 healthy volunteers received either placebo (n = 27), 1 or 2 g/day (n = 27 and n = 28, respectively) for a month [130]. Of the 82 volunteers, 80 completed the trial; only two, both female, randomized to receive 2 g/day of the total extract withdrew, one due to insomnia and palpitations after seven days, and the other due to non-health related reasons. Administration of the total extract improved the serum levels of anti-oxidant markers. In another randomized, double-blind, placebo-controlled trial investigating the anti-oxidant effects in postmenopausal women, 41 volunteers received placebo and 41 received 1 g of the extract thrice daily for 12 weeks [131]. Five volunteers receiving placebo and six receiving the extract failed to complete the trial. Administration of the total extract increased the enzyme activity of the serum antioxidant, superoxide dismutase, suggesting that the total extract may reduce oxidative stress in postmenopausal women. At this dose, reported side effects included dizziness, sleeplessness, nervousness, and uterine bleeding [131]. Adverse effects following administration of 1 or 2 g/day of total extract of ginseng to healthy subjects for a month were reported to be mild (constipation and dyspepsia, insomnia, and hot flush) and it was concluded that this extract does not cause serious adverse reactions and is safe and tolerable [132].

6.2. Clinical Trials and Application of Rg3 in Cancer Patients

Presently, there are only three published clinical trials utilizing Rg3 in the treatment of cancer; two on non-small cell lung carcinoma (NSCLC) [95] [96] and one on hepatocellular carcinoma...
(HCC) [99]. In the first study, a total of 133 patients with stage II-III NSCLC received either Rg3 alone (43 cases), Rg3 + chemotherapy (46 cases), or chemotherapy alone (44 cases) [133]. Rg3 was administered twice a day (0.8 mg/kg, equivalent to 40–50 mg/day) for at least 6 months. This study showed that Rg3 + chemotherapy improved the 3-year survival rates compared to either Rg3 or chemotherapy alone (54.3% versus either 46.5% or 47.7%, respectively; p > 0.05). In patients expressing VEGF, chemotherapy treatment alone resulted in decreased 3-year survival rates compared to patients with negative VEGF expression (p < 0.01); however, there were no significant differences for the other two groups. In addition, patients that received Rg3 had a lower incidence of adverse effects and better immune system function, as evidenced by the increased activity of NK cells and CD4+ T cells and the normal ratio of CD4+/CD8+ T cells [133]. This suggests that the option of combining Rg3 therapy with immunotherapy would be worth investigating.

In the second study, 124 patients with advanced (stage III-IV), unresectable NSCLC with EGFR mutations were divided into two groups receiving a tyrosine kinase inhibitor (TKI) + Rg3 (20 mg orally for at least 2 months) or TKI alone [134]. The results of this study demonstrated that Rg3 improved the median progression-free survival by 2.5 months (p = 0.049). Rg3 delayed the acquired resistance to TKI and had a low toxicity profile, with rash being the worst side effect in both groups and nausea, diarrhea, and anorexia being the most common side effects in both groups [134].

In the third study, 228 patients diagnosed with advanced (Barcelona clinic liver cancer-stage C) HCC were randomized in two groups, to receive trans-arterial chemoembolization (TACE) alone or in combination with Rg3 (20 mg, twice a day, orally) [135]. TACE is a successful method for delivering chemotherapy directly to the tumor within the liver which prolongs patient survival, but its application is limited by high recurrence rate, in part due to inflammatory factors promoting metastasis of the tumor. Inflammation and angiogenesis are associated phenomena in that pro-inflammatory cytokines such as IL-1ß or TNF-α released from activated neutrophils and macrophages cause vasculature modifications, enhancing proliferation of endothelial cells and hyper-neovascularization [136,137]. Hence, using an anti-angiogenic drug should limit this adverse effect. This study showed that the patients receiving TACE + Rg3 had longer median overall survival compared to those who received TACE alone (13.2 versus 10 months; p = 0.002), while there was no significant difference in progression free survival. Rg3 was well-tolerated, the reported adverse effects being grade 1 or 2 constipation, epistaxis, and hypertension, and importantly, Rg3 treatment tended to alleviate adverse effects related to TACE [135].

7. Conclusions

So far, many studies have shown the effects of Rg3 in different cancer models with fewer studies in human clinical trials. A limited number of studies have focused on the effects of Rg3 in breast cancer models and more specifically in advanced breast cancer. Out of the six studies on the effects of Rg3 in breast cancer, only one study has focused on the effects of an isomer, 20(S)-Rg3, and its in vivo effects in mice in increasing the efficacy of oral paclitaxel [79]. The rest of these studies used Rg3 as a whole compound [30,31,69,81,138]. In some cases, the source of the Rg3 used is self-produced, and of unknown purity [30,31]. Given the fact that Rg3 can have stereospecific activities [24,28,29], a mixture of two enantiomers, with unknown ratios of each enantiomer, cannot scientifically justify the resulting effects. With this view, stereospecific activity of Rg3 in human breast cancer models, including cell lines and patient tumor-derived cancer cells, in 2D and 3D in vitro models, and in vivo, is not known. Furthermore, considering the importance of AQP1 in angiogenesis and the invasiveness of tumors, together with evidence of survival benefit from clinical trials, the selectivity of Rg3 in targeting AQP1 in metastatic breast tumors should be studied.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Giuliano, A.E.; Connolly, J.L.; Edge, S.B.; Mittendorf, E.A.; Rugo, H.S.; Solin, L.J.; Weaver, D.L.; Winchester, D.J.; Hortobagyi, G.N. Breast cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin. 2017, 67, 290–303. [CrossRef] [PubMed]

2. Eckstein, N. Platinum resistance in breast and ovarian cancer cell lines. J. Exp. Clin. Cancer Res. 2011, 30, 1. [CrossRef] [PubMed]

3. Cronin, K.A.; Harlan, L.C.; Dodd, K.W.; Abrams, J.S.; Ballard-Barbash, R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010, 28, 963–968. [CrossRef] [PubMed]

4. Fischer, O.M.; Streit, S.; Hart, S.; Ullrich, A. Beyond herceptin and gleevec. Curr. Opin. Chem. Biol. 2003, 7, 490–495. [CrossRef]

5. Elias, A.D. Triple-negative breast cancer: A short review. Am. J. Clin. Oncol. 2010, 33, 637–645. [CrossRef] [PubMed]

6. Eisenberg, S. Systemic Therapy. In Breast Cancer; Mahon, S.M., Ed.; Oncology Nursing Society: Pittsburgh, PA, USA, 2011.

7. Anders, C.K.; Carey, L.A. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin. Breast Cancer 2009, 9, S73–S81. [CrossRef] [PubMed]

8. Robert, N.; Leyland-Jones, B.; Asmar, L.; Belt, R.; Ilegbodu, D.; Loesch, D.; Raju, R.; Valentine, E.; Sayre, R.; Cobleigh, M. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2006, 24, 2786–2792. [CrossRef]

9. Attele, A.S.; Wu, J.A.; Yuan, C.-S. Ginseng pharmacology: Multiple constituents and multiple actions. Biochem. Pharmacol. 1999, 58, 1685–1693. [CrossRef]

10. Park, J.D.; Rhee, D.K.; Lee, Y.H. Biological activities and chemistry of saponins from Panax ginseng CA Meyer. Phytochem. Rev. 2005, 4, 159–175. [CrossRef]

11. Park, H.J.; Kim, D.H.; Park, S.J.; Kim, J.M.; Ryu, J.H. Ginseng in traditional herbal prescriptions. J. Ginseng Res. 2012, 36, 225. [CrossRef] [PubMed]

12. Yang, M.S.; Wu, M.Y. Chinese ginseng. In Nutraceuticals; Elsevier: New York City, NY, USA, 2016; pp. 693–705.

13. Chang-Xiao, L.; Pei-Gen, X. Recent advances on ginseng research in China. J. Ethnopharmacol. 1992, 36, 27–38. [CrossRef]

14. Choi, K.-T. Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng CA Meyer. Acta Pharmacol. Sin. 2008, 29, 1109. [CrossRef] [PubMed]

15. Wang, C.-Z.; Aung, H.H.; Ni, M.; Wu, J.-A.; Tong, R.; Wicks, S.; He, T.-C.; Yuan, C.-S. Red American ginseng: Ginsenoside constituents and antiproliferative activities of heat-processed Panax quinquefolius roots. Planta Med. 2007, 73, 669. [CrossRef] [PubMed]

16. Sun, S.; Wang, C.-Z.; Tong, R.; Li, X.-L.; Fishbein, A.; Wang, Q.; He, T.-C.; Du, W.; Yuan, C.-S. Effects of steaming the root of Panax notoginseng on chemical composition and anticancer activities. Food Chem. 2010, 118, 307–314. [CrossRef]

17. Chang, Y.H.; Ng, P.K. Effects of Extrusion process variables on extractable ginsenosides in wheat-ginseng extrudates. J. Agric. Food Chem. 2009, 57, 2356–2362. [CrossRef] [PubMed]

18. Ren, G.; Chen, F. Degradation of ginsenosides in American ginseng (Panax quinquefolium) extracts during microwave and conventional heating. J. Agric. Food Chem. 1999, 47, 1501–1505. [CrossRef] [PubMed]

19. Kang, D.-I.; Lee, J.-Y.; Yang, J.-Y.; Jeong, S.M.; Lee, J.-H.; Nah, S.-Y.; Kim, Y. Evidence that the tertiary structure of 20(S)-ginsenoside Rg3 with tight hydrophobic packing near the chiral center is important for Na+ channel regulation. Biochem. Biophys. Res. Commun. 2005, 333, 1194–1201. [CrossRef] [PubMed]

20. Qi, L.-W.; Wang, C.-Z.; Yuan, C.-S. Ginsenosides from American ginseng: Chemical and pharmacological diversity. Phytochemistry 2011, 72, 689–699. [CrossRef] [PubMed]

21. Jeong, S.M.; Lee, J.-H.; Kim, J.-H.; Lee, B.-H.; Yoon, I.-S.; Lee, J.-H.; Kim, D.-H.; Rhim, H.; Kim, Y.; Nah, S.-Y. Stereospecificity of Ginsenoside Rg 3 Action on Ion Channels. Mol Cells 2004, 18, 383–389. [PubMed]

22. Kim, J.-H.; Lee, J.-H.; Jeong, S.M.; Lee, B.-H.; Yoon, I.-S.; Lee, J.-H.; Choi, S.-H.; Kim, D.-H.; Park, T.-K.; Kim, B.-K. Stereospecific effects of ginsenoside Rg3 epimers on swine coronary artery contractions. Biol. Pharm. Bull. 2006, 29, 365–370. [CrossRef]
40. Xie, Q.; Wen, H.; Zhang, Q.; Zhou, W.; Lin, X.; Xie, D.; Liu, Y. Inhibiting PI3K-Akkt signaling pathway is
28. Wu, R.; Ru, Q.; Chen, L.; Ma, B.; Li, C. Stereospecificity of Ginsenoside Rg3 in the Promotion of Cellular
23. Lee, Y.J.; Kim, H.Y.; Kang, K.S.; Lee, J.G.; Yokozawa, T.; Park, J.H. The chemical and hydroxyl radical scavenging activity changes of ginsenoside-Rb1 by heat processing. Bioorg. Med. Chem. Lett. 2008, 18, 4515–4520. [CrossRef] [PubMed]
24. Park, E.-H.; Kim, Y.-J.; Yamabe, N.; Park, S.-H.; Kim, H.-K.; Jang, H.-J.; Kim, J.H.; Cheon, G.J.; Ham, J.; Kang, K.S. Stereospecific anticancer effects of ginsenoside Rg3 epimers isolated from heat-processed American ginseng on human gastric cancer cell. J. Ginseng Res. 2014, 38, 22–27. [CrossRef] [PubMed]
25. Teng, S.; Wang, Y.; Li, P.; Liu, J.; Wei, A.; Wang, H.; Meng, X.; Pan, D.; Zhang, X. Effects of R type and S type ginsenoside Rg3 on DNA methylation in human hepatocarcinoma cells. Mol. Med. Rep. 2017, 15, 2029–2038. [CrossRef] [PubMed]
26. Wei, X.; Su, F.; Su, X.; Hu, T.; Hu, S. Stereospecific antioxidant effects of ginsenoside Rg3 on oxidative stress induced by cyclophosphamide in mice. Fitoterapia 2012, 83, 636–642. [CrossRef] [PubMed]
27. Wei, X.; Chen, J.; Su, F.; Su, X.; Hu, T.; Hu, S. Stereospecificity of ginsenoside Rg3 in promotion of the immune response to ovalbumin in mice. Int. Immunol. 2012, 24, 465–471. [CrossRef] [PubMed]
28. Wu, R.; Ru, Q.; Chen, L.; Ma, B.; Li, C. Stereospecificity of Ginsenoside Rg3 in the Promotion of Cellular Immunity in Hepatoma H22-Bearing Mice. J. Food Sci. 2014, 79, H1430–H1435. [CrossRef] [PubMed]
29. Kim, Y.-J.; Choi, W.-I.; Jeon, B.-N.; Choi, K.-C.; Kim, K.; Kim, T.-J.; Ham, J.; Jang, H.J.; Kang, K.S.; Ko, H. Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-β1-induced epithelial–mesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance. Toxicology 2014, 322, 23–33. [CrossRef] [PubMed]
30. Kim, B.-M.; Kim, D.-H.; Park, J.-H.; Na, H.-K.; Surh, Y.-J. Ginsenoside Rg3 induces apoptosis of human breast cancer (MDA-MB-231) cells. J. Cancer Prev. 2013, 18, 177. [CrossRef] [PubMed]
31. Kim, B.-M.; Kim, D.-H.; Park, J.-H.; Surh, Y.-J.; Na, H.-K. Ginsenoside Rg3 inhibits constitutive activation of NF-κB signaling in human breast cancer (MDA-MB-231) cells: ERK and Akt as potential upstream targets. J. Cancer Prev. 2014, 19, 23. [CrossRef]
32. Wu, K.; Li, N.; Sun, H.; Xu, T.; Jin, F.; Nie, J. Endoplasmic reticulum stress activation mediates Ginseng Rg3-induced anti-gallbladder cancer cell activity. Biochem. Biophys. Res. Commun. 2015, 466, 369–375. [CrossRef]
33. Aziz, F.; Wang, X.; Liu, J.; Yan, Q. Ginsenoside Rg3 induces FUT4-mediated apoptosis in H. pylori CagA-treated gastric cancer cells by regulating SP1 and HSF1 expressions. Toxicol. In Vitro 2016, 31, 158–166. [CrossRef] [PubMed]
34. Kim, B.J.; Nah, S.Y.; Jeon, J.H.; So, I.; Kim, S.J. Transient Receptor Potential Melastatin 7 Channels are Involved in Ginsenoside Rg3-Induced Apoptosis in Gastric Cancer Cells. Basic Clin. Pharmacol. Toxicol. 2011, 109, 233–239. [CrossRef] [PubMed]
35. Luo, Y.; Zhang, P.; Zeng, H.Q.; Lou, S.F.; Wang, D.X. Ginsenoside Rg3 induces apoptosis in human multiple myeloma cells via the activation of Bcl-2-associated X protein. Mol. Med. Rep. 2015, 12, 3557–3562. [CrossRef] [PubMed]
36. Shan, X.; Tian, L.L.; Zhang, Y.M.; Wang, X.Q.; Yan, Q.; Liu, J.W. Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-κB/p65 signaling pathway to promote melanoma cell death. Int. J. Oncol. 2015, 47, 701–709. [CrossRef]
37. Choi, Y.J.; Lee, H.J.; Kang, D.W.; Han, I.H.; Choi, B.K.; Cho, W.H. Ginsenoside Rg3 induces apoptosis in the U87MG human glioblastoma cell line through the MEK signaling pathway and reactive oxygen species. Oncol. Rep. 2013, 30, 1362–1370. [CrossRef] [PubMed]
38. Joo, E.J.; Chun, J.; Ha, Y.W.; Ko, H.J.; Xu, M.-Y.; Kim, Y.S. Novel roles of ginsenoside Rg3 in apoptosis through downregulation of epidermal growth factor receptor. Chem. Biol. Interact. 2015, 233, 25–34. [CrossRef] [PubMed]
39. Jiang, J.-W.; Chen, X.-M.; Chen, X.-H.; Zheng, S.-S. Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via intrinsic apoptotic pathway. World J. Gastroenterol. 2011, 17, 3605. [CrossRef]
40. Xie, Q.; Wen, H.; Zhang, Q.; Zhou, W.; Lin, X.; Xie, D.; Liu, Y. Inhibiting PI3K-Akt signaling pathway is involved in antitumor effects of ginsenoside Rg3 in lung cancer cell. Biomed. Pharmacother. 2017, 85, 16–21. [CrossRef]
41. Sun, H.Y.; Lee, J.H.; Han, Y.-S.; Yoon, Y.M.; Yun, C.W.; Kim, J.H.; Song, Y.S.; Lee, S.H. Pivotal roles of ginsenoside Rg3 in tumor apoptosis through regulation of reactive oxygen species. Anticancer Res. 2016, 36, 4647–4654. [CrossRef]
Yang, L.Q.; Wang, B.; Gan, H.; Fu, S.T.; Zhu, X.X.; Wu, Z.N.; Zhan, D.W.; Gu, R.L.; Dou, G.F.; Meng, Z.Y.

Yue, P.Y.; Wong, D.Y.; Wu, P.; Leung, P.; Ip, G. Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin. Med. J. 2008, 121, 1394–1397.

Lee, S.G.; Kang, Y.J.; Nam, J.-O. Anti-metastasis effects of ginsenoside Rg3 in B16F10 cells. J. Microbiol. Biotechnol. 2015, 25, 1997–2006. [CrossRef]

Liu, T.; Zhao, L.; Zhang, Y.; Chen, W.; Liu, D.; Hou, H.; Ding, L.; Li, X. Ginsenoside 20 (S)-Rg3 targets HIF-1α to block hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells. PLoS ONE 2014, 9, e103887. [CrossRef]

Chen, X.-P.; Qian, L.-J.; Jiang, H.; Chen, J.-H. Ginsenoside Rg3 inhibits CXCR 4 expression and related migration in a breast cancer cell line. Int. J. Clin. Oncol. 2011, 16, 519–523. [CrossRef] [PubMed]

Mochizuki, M.; Yoo, Y.; Matsuzawa, K.; Sato, K.; Saiki, I.; Tonooka, S.; Samukawa, K.; Azuma, I. Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside-Rb2, 20 (R)- and 20 (S)-ginsenoside-Rg3, of red ginseng. Biol. Pharm. Bull. 1995, 18, 1197–1202. [CrossRef]

Pan, X.-Y.; Guo, H.; Han, J.; Hao, F.; An, Y.; Xu, Y.; Xiaokaiyi, Y.; Pan, Y.; Li, X.-J. Ginsenoside Rg3 attenuates cell migration via inhibition of aquaporin 1 expression in PC-3M prostate cancer cells. Eur. J. Pharmacol. 2012, 683, 27–34. [CrossRef]

Park, D.; Bae, D.-K.; Jeon, J.H.; Lee, J.; Oh, N.; Yang, G.; Yang, Y.-H.; Kim, T.K.; Song, J.; Lee, S.H. Immunopotentiation and antitumor effects of a ginsenoside Rg3-fortified red ginseng preparation in mice bearing H460 lung cancer cells. Environ. Toxicol. Pharmacol. 2011, 31, 397–405. [CrossRef]

Wang, L.; Li, X.; Song, Y.M.; Wang, B.; Zhang, F.R.; Yang, R.; Wang, H.Q.; Zhang, G.J. Ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to γ-radiation by targeting the nuclear factor-κB pathway. Mol. Med. Rep. 2015, 12, 609–614. [CrossRef] [PubMed]

Kwon, H.-Y.; Kim, E.-H.; Kim, S.-W.; Kim, S.-N.; Park, J.-D.; Rhee, D.-K. Selective toxicity of ginsenoside Rg 3 on multidrug resistant cells by membrane fluidity modulation. Arch. Pharm. Res. 2008, 31, 171–177. [CrossRef] [PubMed]

Zhang, Y.-H.; Li, H.-D.; Li, B.; Jiang, S.-D.; Jiang, L.-S. Ginsenoside Rg3 induces DNA damage in human osteosarcoma cells and reduces MNNG-induced DNA damage and apoptosis in normal human cells. Oncol. Rep. 2014, 31, 919–925. [CrossRef] [PubMed]

Guo, J.-Q.; Zheng, Q.-H.; Chen, H.; Chen, L.; Xu, J.-B.; Chen, M.-Y.; Lu, D.; Wang, Z.-H.; Tong, H.-F.; Lin, S. Ginsenoside Rg3 inhibition of vasulogenic mimicry in pancreatic cancer through downregulation of VE-cadherin/EphA2/MMP9/MMP2 expression. Int. J. Oncol. 2014, 45, 1065–1072. [CrossRef] [PubMed]

Yue, P.Y.; Wong, D.Y.; Wu, P.; Leung, P.; Mak, N.; Yeung, H.; Liu, L.; Cai, Z.; Jiang, Z.-H.; Fan, T. The angiossuppressive effects of 20 (R)-ginsenoside Rg3. Biochem. Pharmacol. 2006, 72, 437–445. [CrossRef] [PubMed]

Tang, H.; Ren, Y.; Zhang, J.; Ma, S.; Gao, F.; Wu, Y. Correlation of insulin-like growth factor-1 (IGF-1) to angiogenesis of breast cancer in IGF-1-deficient mice. Ai Zhong 2007, 26, 1215–1220. [PubMed]

Yang, L.Q.; Wang, B.; Gan, H.; Fu, S.T.; Zhu, X.X.; Wu, Z.N.; Zhan, D.W.; Gu, R.L.; Dou, G.F.; Meng, Z.Y. Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20 (S)-ginsenoside Rg3 in vivo. Biopharm. Drug Dispos. 2012, 33, 425–436. [CrossRef] [PubMed]

Kim, S.-W.; Kwon, H.-Y.; Chi, D.-W.; Shim, J.-H.; Park, J.-D.; Lee, Y.-H.; Pyo, S.; Rhee, D.-K. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3. Biochem. Pharmacol. 2003, 65, 75–82. [CrossRef]
82. Zhang, Q.; Kang, X.; Zhao, W. Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma. *Biochem. Biophys. Res. Commun.* 2006, 342, 824–828. [CrossRef]
83. Zhang, Q.H.; Wu, C.F.; Duan, L.; Yang, J.Y. Protective effects of ginsenoside Rg3 against cyclophosphamide-induced DNA damage and cell apoptosis in mice. *Arch. Toxicol.* 2008, 82, 117–123. [CrossRef] [PubMed]
84. Liu, T.-G.; Huang, Y.; Cui, D.-D.; Huang, X.-B.; Mao, S.-H.; Ji, L.-L.; Song, H.-B.; Yi, C. Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. *BMC Cancer* 2009, 9, 250. [CrossRef] [PubMed]
85. Sun, C.; Yu, Y.; Wang, L.; Wu, B.; Xia, L.; Feng, F.; Ling, Z.; Wang, S. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro. *J. Exp. Clin. Cancer Res.* 2016, 35, 32. [CrossRef] [PubMed]
86. Lee, C.K.; Park, K.-K.; Chung, A.-S.; Chung, W.-Y. Ginsenoside Rg3 enhances the chemosensitivity of tumors to cisplatin by reducing the basal level of nuclear factor erythroid 2-related factor 2-mediated heme oxygenase-1/NAD (P) H quinone oxidoreductase-1 and prevents normal tissue damage by scavenging cisplatin-induced intracellular reactive oxygen species. *Food Chem. Toxicol.* 2012, 50, 2565–2574. [PubMed]
87. Lee, Y.J.; Lee, S.; Ho, J.N.; Byun, S.-S.; Hong, S.K.; Lee, S.E.; Lee, E. Synergistic antitumor effect of ginsenoside Rg3 and cisplatin in cisplatin-resistant bladder tumor cell line. *Oncol. Rep.* 2014, 32, 1803–1808. [CrossRef] [PubMed]
88. Chang, L.; Huo, B.; Lv, Y.; Wang, Y.; Liu, W. Ginsenoside Rg3 enhances the inhibitory effects of chemotherapy on esophageal squamous cell carcinoma in mice. *Mol. Clin. Oncol.* 2014, 2, 1043–1046. [CrossRef] [PubMed]
89. Kim, S.M.; Lee, S.Y.; Yuk, D.Y.; Moon, D.C.; Choi, S.S.; Kim, Y.; Han, S.B.; Oh, K.-W.; Hong, J.T. Inhibition of NF-κB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. *Arch. Pharm. Res.* 2009, 32, 755–765. [CrossRef] [PubMed]
90. Kim, S.M.; Lee, S.Y.; Cho, J.S.; Son, S.M.; Choi, S.S.; Yun, Y.P.; Yoo, H.S.; Oh, K.-W.; Han, S.B.; Hong, J.T. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-κB. *Eur. J. Pharmacol.* 2010, 631, 1–9. [CrossRef] [PubMed]
91. Kim, D.-G.; Jung, K.H.; Lee, D.-G.; Yoon, J.-H.; Choi, K.S.; Kwon, S.W.; Shen, H.-M.; Morgan, M.J.; Hong, S.-S.; Kim, Y.-S. (S)-Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin. *Oncotarget* 2014, 5, 4438. [CrossRef] [PubMed]
92. Wang, X.; Chen, L.; Wang, T.; Jiang, X.; Zhang, H.; Li, P.; Lv, B.; Gao, X. Ginsenoside Rg3 antagonizes adriamycin-induced cardiotoxicity by improving endothelial dysfunction from oxidative stress via upregulating the Nrtr2-ARE pathway through the activation of akt. *Phytomedicine* 2015, 22, 875–884. [CrossRef]
93. Che, J.-B.; Liu, Z.-H.; Ma, H.-B.; Li, Y.; Zhao, H.; Li, X.-H.; Liu, W.-C.; Shi, G.-N. Influence of As2O3 combined with ginsenosides Rg3 on inhibition of lung cancer NCI-H1299 cells and on subsistence of nude mice bearing hepatoma. *Asian Pac. J. Trop. Med.* 2014, 7, 772–775. [CrossRef]
94. Yool, A.J.; Brown, E.A.; Flynn, G.A. Roles for novel pharmacological blockers of aquaporins in the treatment of brain oedema and cancer. *Clin. Exp. Pharmacol. Physiol.* 2010, 37, 403–409. [CrossRef] [PubMed]
95. Yool, A.J. Functional domains of aquaporin-1: Keys to physiology, and targets for drug discovery. *Curr. Pharm. Des.* 2007, 13, 3212–3221. [CrossRef] [PubMed]
96. Dorward, H.S.; Du, A.; Bruhn, M.A.; Wrin, J.; Pei, J.V.; Evdokiou, A.; Price, T.J.; Yool, A.J.; Hardingham, J.E. Pharmacological blockade of aquaporin-1 water channel by AqB013 restricts migration and invasiveness of colon cancer cells and prevents endothelial tube formation in vitro. *J. Exp. Clin. Cancer Res.* 2016, 35, 36. [CrossRef] [PubMed]
97. Papadopoulo, M.; Saadoun, S.; Verkman, A. Aquaporins and cell migration. *Pflüg. Arch.* 2008, 456, 693–700. [CrossRef] [PubMed]
98. Hu, J.; Verkman, A.; Hu, J.; Verkman, A. Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. *FASEB J.* 2006, 20, 1892–1894. [CrossRef] [PubMed]
99. Wragg, J.W.; Heath, V.L.; Bicknell, R. Sunitinib treatment enhances metastasis of innately drug resistant breast tumors. *Cancer Res.* 2016, 77, 1008–1020. [CrossRef] [PubMed]
100. Verkman, A.; Hara-Chikuma, M.; Papadopoulo, M.C. Aquaporins—New players in cancer biology. *J. Mol. Med.* 2008, 86, 523–529. [CrossRef]
101. Agre, P.; Preston, G.M.; Smith, B.L.; Jung, J.S.; Raina, S.; Moon, C.; Guggino, W.B.; Nielsen, S. Aquaporin CHIP: The archetypal molecular water channel. *Am. J. Physiol. Ren. Physiol.* 1993, 265, F463–F476. [CrossRef]

102. Yool, A.J.; Campbell, E.M. Structure, function and translational relevance of aquaporin dual water and ion channels. *Mol. Asp. Med.* 2012, 33, 553–561. [CrossRef] [PubMed]

103. De Liso, M.L.; Yool, A.J. Mechanisms of Aquaporin-Facilitated Cancer Invasion and Metastasis. *Front. Chem.* 2018, 6, 135. [CrossRef] [PubMed]

104. Campbell, E.M.; Birdsell, D.N.; Yool, A.J. The activity of human aquaporin 1 as a cGMP-gated cation channel is regulated by tyrosine phosphorylation in the carboxyl terminal domain. *Mol. Pharmacol.* 2011, 81, 97–105. [CrossRef] [PubMed]

105. Baetz, N.W.; Stamer, W.D.; Yool, A.J. Aquaporin 1 (AQP1) expression is a novel characteristic feature of a particularly aggressive subgroup of basal-like breast carcinomas. *J. Surg. Oncol.* 2012, 106, 267–272. [CrossRef] [PubMed]

106. Qin, F.; Zhang, H.; Shao, Y.; Liu, X.; Yang, L.; Huang, Y.; Fu, L.; Gu, F.; Ma, Y. Expression of aquaporin1, a water channel protein, in cytoplasm is negatively correlated with prognosis of breast cancer patients. *Oncotarget* 2016, 7, 8143. [CrossRef] [PubMed]

107. Zou, L.-B.; Shi, S.; Zhang, R.-J.; Wang, T.-T.; Tan, Y.-J.; Zhang, D.; Fei, X.-Y.; Ding, G.-L.; Gao, Q.; Chen, C. Aquaporin-1 plays a crucial role in estrogen-induced tubulogenesis of vascular endothelial cells. *J. Clin. Endocrinol. Metab.* 2013, 98, E672–E682. [CrossRef] [PubMed]

108. Endo, M.; Jain, R.K.; Witwer, B.; Brown, D. Water channel (aquaporin 1) expression and distribution in mammary carcinomas and glioblastomas. *Microvasc. Res.* 1999, 58, 89–98. [CrossRef] [PubMed]

109. Saadoun, S.; Papadopoulos, M.C.; Hara-Chikuma, M.; Verkman, A. Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. *Nature* 2005, 434, 786. [CrossRef]

110. Saadoun, S.; Papadopoulos, M.C.; Hara-Chikuma, M.; Verkman, A. Aquaporin-1 gene deletion reduces breast tumor growth and lung metastasis in tumor-producing MMTV-PyVT mice. *FASEB J.* 2014, 28, 1446–1453. [CrossRef]

111. Mobasheri, A.; Shakibaei, M.; Marples, D. Immunohistochemical localization of aquaporin 10 in the apical membranes of the human ileum: A potential pathway for luminal water and small solute absorption. *Histochem. Cell Biol.* 2004, 121, 463–471. [CrossRef]

112. Mobasher, A.; Airley, R.; Hewitt, S.M.; Marples, D. Heterogeneous expression of the aquaporin 1 (AQP1) water channel in tumors of the prostate, breast, ovary, colon and lung: A study using high density multiple human tumor tissue microarrays. *Int. J. Oncol.* 2005, 26, 1149–1158. [CrossRef]

113. Shi, Z.; Zhang, T.; Luo, L.; Zhao, H.; Cheng, J.; Xiang, J.; Zhao, C. Aquaporins in human breast cancer: Identification and involvement in carcinogenesis of breast cancer. *J. Surg. Oncol.* 2012, 106, 267–272. [CrossRef] [PubMed]

114. Otterbach, F.; Callies, R.; Adamzik, M.; Kimmig, R.; Siffert, W.; Schmid, K.W.; Bankfalvi, A. Aquaporin 1 (AQP1) expression is a novel characteristic feature of a particularly aggressive subgroup of basal-like breast carcinomas. *Breast Cancer Res. Treat.* 2010, 120, 67–76. [CrossRef] [PubMed]

115. Zhang, B.; Liu, F.; Ma, Y.; Gu, F. Cytoplasmic expression of aquaporin-1 in breast cancer cells and its relationship with clinicopathological characteristics and prognosis. *Zhonghua Zhong Liu Za Zhi* 2013, 35, 904–909. [PubMed]

116. Kanoaka, M. Metabolism of ginseng saponins, ginsenosides, by human intestinal bacteria. *J. Trad. Med.* 1994, 11, 241–245.

117. Karikura, M.; Miyase, T.; Tanizawa, H.; Taniyama, T.; Takino, Y. Studies on absorption, distribution, excretion and metabolism of ginseng saponins. VII. Comparison of the decomposition modes of ginsenoside-Rb1 and-Rb2 in the digestive tract of rats. *Chem. Pharm. Bull.* 1991, 39, 2357–2361. [CrossRef] [PubMed]

118. Lee, J.; Lee, E.; Kim, D.; Lee, J.; Yoo, J.; Koh, B. Studies on absorption, distribution and metabolism of ginseng in humans after oral administration. *J. Ethnopharmacol.* 2009, 122, 143–148. [CrossRef] [PubMed]

119. Hao, M.; Zhao, Y.; Chen, P.; Huang, H.; Liu, H.; Jiang, H.; Zhang, R.; Wang, H. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. *PLoS ONE* 2008, 3, e2697. [CrossRef]

120. Bae, E.-A.; Han, M.J.; Choo, M.-K.; Park, S.-Y.; Kim, D.-H. Metabolism of 20 (S)-and 20 (R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities. *Biol. Pharm. Bull.* 2002, 25, 58–63. [CrossRef]
121. Lu, J.-M.; Yao, Q.; Chen, C. Ginseng compounds: An update on their molecular mechanisms and medical applications. *Curr. Vasc. Pharmacol.* 2009, 7, 293–302. [CrossRef]

122. Li, K.; Chen, X.; Xu, J.; Li, X.; Zhong, D. Liquid chromatography/tandem mass spectrometry for pharmacokinetic studies of 20 (R)-ginsenoside Rg3 in dog. *Rapid Commun. Mass Spectrom.* 2005, 19, 813–817. [CrossRef]

123. Qian, T.; Cai, Z.; Wong, R.N.; Mak, N.K.; Jiang, Z.-H. In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. *J. Chromatogr. B* 2005, 816, 223–232. [CrossRef]

124. Cai, Z.; Qian, T.; Wong, R.N.; Jiang, Z.-H. Liquid chromatography–electrospray ionization mass spectrometry for metabolism and pharmacokinetic studies of ginsenoside Rg3. *Anal. Chim. Acta* 2003, 492, 283–293. [CrossRef]

125. Xie, H.-T.; Wang, G.-J.; Sun, J.-G.; Tucker, I.; Zhao, X.-C.; Xie, Y.-Y.; Li, H.; Jiang, X.-L.; Wang, R.; Xu, M.-J. High performance liquid chromatographic–mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. *J. Chromatogr. B* 2005, 818, 167–173. [CrossRef] [PubMed]

126. Zhao, Q.; Zheng, X.; Jiang, J.; Zhou, H.; Hu, P. Determination of ginsenoside Rg3 in human plasma and urine by high performance liquid chromatography–tandem mass spectrometry. *J. Chromatogr. B* 2010, 878, 2266–2273. [CrossRef]

127. Huan, P.; Hailin, W.; Li, F.; Chengye, S. Pharmacokinetics of 20 (R)-Ginsenoside Rg3 in Human Volunteers. *JCPs* 2001, 10, 140–143.

128. Bae, S.H.; Park, J.B.; Zheng, Y.F.; Jang, M.J.; Kim, S.O.; Kim, J.Y.; Yoo, Y.H.; Yoon, K.D.; Oh, E.; Bae, S.K. Pharmacokinetics and tissue distribution of ginsenoside Rh2 and Rg3 epimers after oral administration of BST204, a purified ginseng dry extract, in rats. *Xenobiotica* 2014, 44, 1099–1107. [CrossRef] [PubMed]

129. Wang, H.; Zou, H.; Kong, L.; Zhang, Y.; Pang, H.; Su, C.; Liu, G.; Hui, M.; Fu, L. Determination of ginsenoside Rg3 in plasma by solid-phase extraction and high-performance liquid chromatography for pharmacokinetic study. *J. Chromatogr. B Biomed. Sci. Appl.* 1999, 731, 403–409. [CrossRef]

130. Kim, H.-G.; Yoo, S.-R.; Park, H.-J.; Lee, N.-H.; Shin, J.-W.; Sathyananth, R.; Cho, J.-H.; Son, C.G. Antioxidant effects of Panax ginseng CA Meyer in healthy subjects: A randomized, placebo-controlled clinical trial. *Food Chem. Toxicol.* 2011, 49, 2229–2235. [CrossRef]

131. Lee, N.-H.; Yoo, S.-R.; Kim, H.-G.; Cho, J.-H.; Son, C.G. Safety and tolerability of Panax ginseng root extract: A randomized, placebo-controlled, clinical trial in healthy Korean volunteers. *J. Altern. Complement. Med.* 2012, 18, 1061–1069. [CrossRef]

132. Lu, P.; Su, W.; Miao, Z.-H.; Niu, H.-R.; Liu, J.; Hua, Q.-L. Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer. *Chin. J. Integr. Med.* 2008, 14, 33–36. [CrossRef] [PubMed]

133. Li, Y.; Wang, Y.; Niu, K.; Chen, X.; Xia, L.; Lu, D.; Kong, R.; Chen, Z.; Duan, Y.; Sun, J. Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation. *Oncotarget* 2016, 7, 70535. [CrossRef] [PubMed]

134. Zhou, B.; Yan, Z.; Liu, R.; Shi, P.; Qian, S.; Xu, Q.; Zhu, L.; Zhang, W.; Wang, J. Prospective study of transcatheter arterial chemoembolization (TACE) with ginsenoside Rg3 versus TACE alone for the treatment of patients with advanced hepatocellular carcinoma. *Radiology* 2016, 280, 630–639. [CrossRef] [PubMed]

135. Szewczyk, G.; Rak, J.; Ruth, J.H. Inflammatory Mediators of Angiogenesis. *Med. Inflamm.* 2013, 2013, 610543. [CrossRef] [PubMed]
137. Naldini, A.; Carraro, F. Role of inflammatory mediators in angiogenesis. *Curr. Drug Targets Inflamm. Allergy* 2005, 4, 3–8. [CrossRef] [PubMed]

138. Yuan, Z.; Jiang, H.; Zhu, X.; Liu, X.; Li, J. Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer. *Biomed. Pharmacother.* 2017, 89, 227–232. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).